2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow Sells 2,298 Shares

2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow sold 2,298 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $11,375.10. Following the completion of the transaction, the chief operating officer now directly owns 254,193 shares in the company, valued at approximately $1,258,255.35. This represents a 0.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

2seventy bio Price Performance

NASDAQ TSVT opened at $4.96 on Thursday. The company’s 50 day simple moving average is $2.85 and its two-hundred day simple moving average is $3.69. The stock has a market capitalization of $255.88 million, a PE ratio of -2.67 and a beta of 1.73. 2seventy bio, Inc. has a 1 year low of $2.29 and a 1 year high of $5.99.

Analysts Set New Price Targets

Several analysts have commented on TSVT shares. Morgan Stanley lowered their price objective on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Friday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday, March 7th. Leerink Partnrs lowered shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 11th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $5.00 price objective (down from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.67.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH bought a new position in shares of 2seventy bio in the 3rd quarter worth $25,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of 2seventy bio in the 4th quarter worth about $32,000. BNP Paribas Financial Markets bought a new stake in 2seventy bio in the 4th quarter worth approximately $35,000. ProShare Advisors LLC purchased a new stake in 2seventy bio in the fourth quarter worth approximately $48,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of 2seventy bio in the 4th quarter valued at $52,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.